Jamaluddin Moloo, MD
Interventional Cardiology · Aurora, CONPI 1235101197
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Heartflow, Inc. accounts for 99.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $88,607, more than ten times the $220 reported in 2019. Among interventional cardiology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $1539.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$272K
- Cleerly, Inc.$181
- Novo Nordisk$112
- Amgen$102
- Bayer$62
- Novartis$57
- plus $151 from 6 others
Across 7 payments — averaging $3185.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$22K
What the payments were for
- Consulting fees$119,03044%
- Speaking & faculty fees$137,26250%
- Travel & lodging$11,2194%
- Food & beverage$4,9742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 153 | $271,820 |
| Cleerly, Inc. | 3 | $181 |
| Novo Nordisk | 4 | $112 |
| Amgen | 5 | $102 |
| Bayer | 3 | $62 |
| Novartis | 2 | $57 |
| AstraZeneca | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $30 |
| Lilly USA, LLC | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$270,459
- Cleerly Ischemia$130
- Cleerly Labs$130
How this compares
$272,485 in reported general payments places this provider in the 95th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,031 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $945 |
| Atorvastatin Calcium | 11 | $81 |
| Amlodipine Besylate | 15 | $35 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Aurora
- Gareth MorganAurora$536K
- Jenny Zablah AlabiAurora$269K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
- Akhil Rasim ReddyAurora$29K
- John CarrollAurora$25K
- Connie HessAurora$19K
- Aken DesaiAurora$19K
- Neel ButalaAurora$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.